about
Antigen-specific active immunotherapy for ovarian cancerAntigen-specific active immunotherapy for ovarian cancerFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsMyeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacyThe virosome concept for influenza vaccinesVirosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens.Potential target antigens for a universal vaccine in epithelial ovarian cancer.Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands.Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs.Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity.Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7.Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte EpitopesVirosomes for antigen and DNA delivery.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses.Vaccine-based clinical trials in ovarian cancer.Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen.Therapeutic vaccination against chronic hepatitis C virus infection.HPV-specific immunotherapy: key role for immunomodulators.On discounting of health gains from human papillomavirus vaccination: effects of different approaches.Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.
P50
Q24193567-C0685D3D-4909-4D8A-984B-EDE06D45E5D0Q24240962-100F7CF0-0560-46BC-8935-DBE7EC1F57DFQ26865532-07971CC1-D3DE-4A74-9080-DE5B39EE1BFDQ28082461-D4842A6B-F6E4-4EC2-8FBD-A6E70000BF9CQ28262476-BFBAC0C2-A701-4413-97F9-E8FAC719575DQ33964519-01FAB720-27CF-4F46-9810-4E8C3C69F3C5Q34159451-5867021C-C670-480B-9E35-B5DBEC4A78AEQ34505091-D8704BCA-5571-4DE2-A8FC-CFF8D60525C6Q34580293-468E0EF3-FB19-4BDC-BFBA-4E905338AF77Q34995209-55E19087-CB30-4466-8D18-08A9372EED6DQ35053462-9ECD1B3B-E1CD-49FB-82A4-C8A67DC6E331Q35506659-EBD4E713-A863-4B7D-9366-BBDFC5278388Q35826994-1AB96D77-1881-4335-AB4C-AD9790C934B8Q35827003-B0498775-F7AA-4548-A4CB-F990513C6570Q35961174-B238C75D-58B1-486F-AA4E-DFEFB198B407Q36107975-8205F5B0-108E-4B3B-B7FD-422AEB6CA414Q36382896-9A70BA24-827C-47D9-9BEC-6AED80001DCDQ37696017-2F879C00-F899-40D9-AACF-DBE3957EF159Q37892583-7F593E84-EB54-4CEB-98E3-27FE7CB07A50Q38010514-9B76EE0B-BA04-4DB6-BCF7-8D148E6EC6EBQ38030231-DA35931C-FCAA-4579-AC34-99DD41860C44Q38163004-5FC3D731-B2CC-4799-9E39-C1000AF87C90Q39617820-24301FCC-20FE-4B12-BA38-C29A75B10368Q39658155-DEADCE80-F280-424E-8057-FF19C346961BQ39708591-E6BC4163-30A7-4E59-9358-F1C850C81479Q39741508-185CD784-5FA8-4B43-887A-6712AC4632DBQ40169196-CEC7ACA2-45DE-4DCE-8730-1B68A247693DQ40470546-8006DDCC-2D8E-4EC7-9811-31B243474067Q40494014-BC573F9F-60AF-4635-BBD5-928E843497AEQ40581836-CBD4AE09-1BF2-4F2C-8648-BAD143C4E7B1Q40673826-1AF1920D-FAF9-4599-8206-17E058B9242AQ40949444-E16A3E78-EE78-4A4F-974B-562058A63CD2Q41067857-3488A3AB-9081-4574-951A-B9B719925E6EQ41346867-D76E0740-6194-428F-9529-BE18E9056047Q42278547-360375A9-8892-4ABD-879A-9D17DB87B7A5Q44426842-554FE5F4-C1EC-465E-A67D-97BC7045E410Q45388333-BB51DFB4-6407-42E4-89C5-2F0887820D8AQ45421625-33FFA906-5712-48D6-B18A-616B2FBE1807Q46920170-A5D9C0C6-1352-4DBA-8772-046AAAF0C8ECQ51798899-7CB5F5CD-1F81-4ADB-A781-CD72C9143009
P50
description
researcher ORCID ID = 0000-0003-0166-512X
@en
wetenschapper
@nl
name
Toos Daemen
@ast
Toos Daemen
@en
Toos Daemen
@es
Toos Daemen
@nl
type
label
Toos Daemen
@ast
Toos Daemen
@en
Toos Daemen
@es
Toos Daemen
@nl
prefLabel
Toos Daemen
@ast
Toos Daemen
@en
Toos Daemen
@es
Toos Daemen
@nl
P31
P496
0000-0003-0166-512X